ARTICLE | Tools & Techniques
An oasis or a mirage?
August 31, 1998 7:00 AM UTC
Although biotech companies often raise eyebrows by plunging ahead without compelling clinical data or a clear market advantage, Hoechst Marion Roussel AG last week demonstrated that big pharma is not immune to the phenomenon.
HMR said it plans to seek a label expansion for its Refludan lepirudin direct thrombin inhibitor to treat unstable angina in addition to its existing indication for heparin-induced thrombocytopenia (HIT)...